by jtcir-auto | Mar 20, 2025 | Press Releases
Toronto, Ontario–(Newsfile Corp. – March 19, 2025) – COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of...
by jtcir-auto | Mar 20, 2025 | Press Releases
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical,...
by jtcir-auto | Mar 20, 2025 | Press Releases
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical,...
by jtcir-auto | Mar 13, 2025 | Press Releases
No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at...
by jtcir-auto | Mar 13, 2025 | Press Releases
No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at...